Application of combination of gabapentin, neurotropin and sinomenine hydrochloride to preparation of medicine for treating PHN (postherpetic neuralgia)

A technology of neurotropin and sinomenine hydrochloride, which is applied in the field of application of the combination of gabapentin, neurotropin and sinomenine hydrochloride in the preparation of medicines for treating PHN, can solve the problem of large side effects, protracted disease, Patient compliance is not good and other problems, to achieve the effect of high safety, good clinical efficacy and less adverse reactions

Inactive Publication Date: 2019-08-30
HUNAN ZHENGQING PHARM GRP CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The current guidelines recommend the combination of antidepressants, antiepileptic drugs and opioid analgesics, but there are often problems such as large side effects or poor treatment effects, and the disease is often protracted, especially for extrapyramidal disorders caused by antidepressants. Response and addiction to opioids limit the application of the above drug combinations and poor patient compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of gabapentin, neurotropin and sinomenine hydrochloride to preparation of medicine for treating PHN (postherpetic neuralgia)
  • Application of combination of gabapentin, neurotropin and sinomenine hydrochloride to preparation of medicine for treating PHN (postherpetic neuralgia)
  • Application of combination of gabapentin, neurotropin and sinomenine hydrochloride to preparation of medicine for treating PHN (postherpetic neuralgia)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The present invention will be further illustrated below in conjunction with the examples, but the invention is not limited to the specific examples.

[0024] From December 2017 to December 2018, 60 patients with subacute PHN who were diagnosed in a certain department of a certain hospital were divided into the control group and the experimental group according to the random number table method.

[0025] (1) Inclusion criteria: ① meet the diagnostic criteria of subacute PHN of the International Association for the Study of Pain; ② course of disease 1-3 months; ③ age over 50 years; ④ VAS ≥ 5 points; ⑤ no nausea, vomiting, dizziness, constipation, urinary retention ⑥ Have not taken other analgesic drugs that act on the central and peripheral areas 2 weeks before the screening period.

[0026] (2) Exclusion criteria: ①painful diseases with unclear diagnosis; ②those with a history of asthma and allergy to Zhengqing Fengtongning, allergy to any component in gabapentin, patien...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a combination of gabapentin, neurotropin and sinomenine hydrochloride to preparation of a medicine for treating postherpetic neuralgia (PHN). According to theapplication, the sinomenine hydrochloride is a natural plant extracts, has the pharmacological action of resisting inflammation, immunosuppression and the like, and is low in toxicity, small in side effects and free from addiction. When the sinomenine hydrochloride, the gabapentin and the neurotropin are united for preparing the medicine for treating the PHN particularly PHN at the subacute stage,the clinical treatment effects are good, the safety is high, few adverse reactions are caused, and a new method is provided for clinical treatment of the PHN.

Description

technical field [0001] The present invention relates to a new application of a combination of drugs in the preparation of a drug for treating PHN, in particular to the use of a combination of gabapentin, neurotropin and sinomenine hydrochloride in the preparation of a drug for the treatment of PHN, which belongs to the new drug combination administration use. Background technique [0002] Dworkin and Portenoy proposed in 1996 to divide herpes zoster into three stages: acute phase, subacute phase, and chronic phase. Postherpetic neuralgia (PHN), 65% to 75% of middle-aged and elderly patients with herpes zoster will develop PHN, is the most common complication of herpes zoster, with allodynia, spontaneous pain, hyperalgesia and paresthesia Many patients are accompanied by chronic pain characteristics such as anxiety, depression, and sleep disorders, which seriously affect the physical and mental health and quality of life of the majority of patients. Early and effective trea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/36A61K31/196A61K31/485A61P31/22A61P25/02A61P29/00
CPCA61K31/196A61K31/485A61K35/36A61P25/02A61P29/00A61P31/22A61K2300/00
Inventor 张达颖王萌彭晓珊仇萍鄢毅朱梦叶滕健张学学许刚章勇邱觅真
Owner HUNAN ZHENGQING PHARM GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products